| Stereochemistry | ACHIRAL |
| Molecular Formula | C40H63N3O4S2 |
| Molecular Weight | 714.076 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)S(=O)(=O)N(C)C)C=CC=C3)CC1
InChI
InChIKey=KTOYYUONFQWSMW-UHFFFAOYSA-N
InChI=1S/C40H63N3O4S2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-22-40(44)47-32-27-34-25-30-42(31-26-34)28-19-29-43-36-20-17-18-21-38(36)48-39-24-23-35(33-37(39)43)49(45,46)41(2)3/h17-18,20-21,23-24,33-34H,4-16,19,22,25-32H2,1-3H3
Pipotiazine (Piportil), also known as Pipothiazine, is a typical antipsychotic of the phenothiazine class used in the United Kingdom and other countries for the treatment of schizophrenia. Its properties are similar to those of chlorpromazine. Piportil® L4 (pipotiazine palmitate) is the palmitic ester of pipotiazine, a piperidine phenothiazine with antipsychotic properties and weak sedative activity. The esterification of pipotiazine is responsible for its prolonged duration of action. The onset of action appears usually within the first 2 to 3 days after injection and the effects of the drug on psychotic symptoms are significant within one week. Improvement in symptomatology lasts from 3 to 6 weeks, but adequate control may frequently be maintained with one injection every 4 weeks. However, in view of the variations in individual response, careful supervision is required throughout treatment. Piportil L4 has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, Piportil L4 appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions.
CNS Activity
Approval Year
PubMed
Patents
Sample Use Guides
Oral: 5-20 mg daily. Severe: 30 mg daily for brief periods.
Intramuscular: As pipotiazine palmitate: Initially, 25 mg as test dose followed by 25-50 mg after 4 to 7 days. Adjust in increments of 25-50 mg according to response every 4 wk.
Route of Administration:
Other
Rats brain striata were dissected out and put in ice-cold 0.25 M sucrose containing 3 mM imidazole, pH 7.4. The striata were then homogenized by 10 strokes of the right pestle of a Duncan homogenizer. The homogenate was fractionated at 0-4°C by differential centrifugation. The assays were performed in 50 mM Tris-HC1 buffer pH 7.1 containing (mM): 120 NaC1, 5 KC1, 2 CaC12, 1 MgC12, 0.1% ascorbic acid and 10 mkM pargyline. The final protein concentration was 0.29 mg/ml. After 5 rain preincubation at 37°C, [3H]N.propylnorapomorphine (final concentration 0.3 nM) and different concentrations of unlabeled drugs were added. After 24 rain incubation at 37°C, the samples were filtered through
Whatman GF/B glass fibre filters. Radioactivity retained on the filters was measured by liquid scintillation counting.
ACTIVE MOIETY
SUBSTANCE RECORD
